ZYBERNO
Stock Report
Updated Sep 1, 2026

Vivos Therapeutics, Inc. (VVOS)

Healthcare • NASDAQ

$0.17

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
Vivos Therapeutics, Inc. (VVOS) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-107.9%)
Return on Capital (Capital Efficiency):CRITICAL (-310.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Vivos Therapeutics, Inc. (VVOS) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VVOS generated -$18.33M in Owner Earnings. Capital was deployed as follows: $2.24M invested in capital expenditures. Reinvestment rate: -7.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.17
Market Cap:$3.04M

Valuation Multiples (2)

P/S Ratio:0.15x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$12.47M

Price Action & Momentum (3)

Momentum Percentile:1 / 100
% of 52-Week High:3.5%
B. Profitability Assessment

Return Metrics (4)

ROA:-101.8%
Reinvestment Rate:-7.4%
Fundamental Growth Rate (g):23.1%

Margin Analysis (3)

Operating Margin Ttm:-107.9%
Net Margin Ttm:-121.8%
Ebitda Margin:-96.4%

TTM Performance (3)

Gross Margin Ttm:61.9%
Operating Margin Ttm:-107.9%
Net Margin Ttm:-121.8%

Yield Metrics (2)

Earnings Yield:-$553.45
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-168.9%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):8.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.21x
Quick Ratio:0.21x
Cash Ratio:0.09x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-7.36x
Times Interest Earned:-7.36

Capital Structure (4)

Working Capital:-16,176,000.00
Cash And Cash Equivalents:1,774,000.00
Long Term Debt:$3.44M
Net Debt:$9.44M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $20.90M
Linear Growth: 8.1%
📊 Click to view full VVOS Revenue analysis & methodology →
Cost Of Revenue Ttm:$6.90M

Profitability Breakdown (2)

Gross profit TTM: $12.94M
Linear Growth: 8.4%
📊 Click to view full VVOS Gross Profit analysis & methodology →
-$22.55M

Bottom Line Performance (3)

-$25.46M
Income Before Tax:-$25.63M
Ebitda Ttm:-20,151,000.00

Operating Expenses (5)

Operating Expenses:35,486,000.00
R And D Expense:200,000.00
Sga Expense:32,510,000.00
Income Tax Expense:$0.00
Interest Expense:2,704,179.00

Expense Ratios (3)

R And D To Revenue Percentage:3.9%
Sga To Revenue Percentage:630.9%
Ebitda Margin:-96.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$24.14M
Current Assets:$4.21M
Ppe Net:3,640,000.00
Goodwill:8,572,000.00
Intangible Assets:$3.64M

Liability Structure (4)

Total Liabilities:28,130,000.00
Current Liabilities:20,389,000.00
Long Term Debt:$3.44M
Short Term Debt:$7.77M

Equity & Capital (3)

Equity:-$3.99M
Retained Earnings:-$138.52M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:1,438,000.00
Inventory:0.00
Accounts Payable:2,946,000.00

Special Items (2)

Contract Liabilities:583,000.00
Stock Based Compensation:100,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$17.48M-$19.71M

Investment Activities (2)

Investing Cash Flow:-$18.00K
Capital Expenditures Ttm:2,237,000.00

Financing Activities (3)

Financing Cash Flow:$6.11M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,800,000.00
Long Term Debt Issuance:$1.40M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,400,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.90
-$1.90
Earnings Per Share Ttm:-$1.44

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.18
Operating Cash Flow Per Share:-$0.86

Book Value & Capital (2)

Book Value Per Share:-$0.23
Cash Per Share:0.10

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.84x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:14.53x
Days Sales Outstanding Ttm:25.11

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:155.82
Cash Conversion Cycle:-1,129.70
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$18.33M

Damodaran Growth Analysis (2)

Reinvestment Rate:-7.4%
Fundamental Growth Rate (g):23.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):8.1%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):8.4%
Book Value Growth Rate (Linear):-4.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:VVOS
Company Name:Vivos Therapeutics, Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:17.68M
Shares Outstanding Basic:17.68M
Shares Outstanding Diluted:17.68M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 15:46:32 UTC
Data Timestamp:2026-08-21T17:30:13.630708
Scroll to Top